

A VACCINE BREAKTHROUGH THAT WILL CHANGE LIVES HOW WILL IT CHANGE YOUR PROGRAMS?

WHAT IF THERE WERE BETTER AND SAFER TREATMENTS FOR ALLERGY, CANCER OR ANIMAL HEALTH THAT WERE MORE EFFECTIVE THAN ANY VACCINE BEING DEVELOPED ON THE MARKET? WHAT IF YOU COULD GET IN ON THE GROUND FLOOR OF NEW, PATENTED TECHNOLOGY THAT IS ALREADY CHANGING THE VACCINATION GAME?

INTRODUCING LAMP-VAX[™] TECHNOLOGY, A BREAKTHROUGH VACCINE PLATFORM THAT'S TRANSFORMING THE WAY RESEARCHERS BRING VACCINES TO MARKET.

LAMP-is a nucleic acid coding sequence added to DNA/RNA vaccines that directs the immune system to effectively respond to vaccine immunotherapy. It diverts the synthesized protein products of DNA and RNA-based vaccines directly to the lysosome in the dendritic cells, making them readily available to form antigen-MHC-II complexes. These MHC-II complexes, after transport to the cell surface, directly interact with helper T-cells and lead to the production of antibodies & Th1 cytokines, while maintaining enhanced CD8+ cytotoxic T-cell activation.

The result is a greatly enhanced immune response that can promote positive clinical outcomes and ultimately enable effective and safer protection for patients.

LAMP is the "missing link" to effective DNA and RNA vaccinations:

- Add to existing DNA or RNA nucleic acid formulations
- Resuscitate failed vaccine programs
- Add LAMP+DNA or LAMP+RNA prime to existing peptide or protein boost
- Reformulate a protein vaccine as a nucleic acid vaccine


Nucleic acid vaccines with LAMP have many advantages:

- Proprietary, intelligent design methodology
- Efficient and expeditious design and validation (3 months)
- Enhanced safety in allergy format
- Excellent stability with long shelf life
- Economical manufacturing cost
- Multivalent and multiplex capability

HUMANS







ITI has a robust pipeline with several clinical & pre-clinical vaccines in internal development & access to options from Worldwide research laboratories. LAMP immunotherapies have been successfully used in Phase I & II clinical studies & trial results show it is safe and effective for patients with prostate cancer, acute myeloid leukemia, melanoma and pollen allergy.

Contact us. Let us show you how LAMP-vax changes the game.